Help us Develop New Treatments for Fatty Liver in People with HIV :: Tesamorelin Effects on Liver Fat and Histology in HIV - Full Text View - ClinicalTrials.gov

Tesamorelin Effects on Liver Fat and Histology in HIV - Full Text View - ClinicalTrials.gov

The TESLA study is evaluating Egrifta® (tesamorelin), a medication approved by the FDA to decrease excess belly fat in people with HIV, to learn if Egrifta may also reduce liver fat.

You may be eligible to participate in the TESLA clinical research study if you:

   -  Are between 18 and 65 years old

   -  Have been diagnosed with HIV

   -  Have fatty liver

   -  Do not have hepatitis B or C

   -  Do not have cirrhosis

All visits will take place at the National Institutes of Health in Bethesda, Maryland, or Massachusetts General Hospital in Boston, Massachusetts.

Compensation is provided. 

For more information, call: 1-800-411-1222 

(Reference 15-I-0036) (TTY: 1-866-411-1010) Se habla español